1. Home
  2. OI vs SUPN Comparison

OI vs SUPN Comparison

Compare OI & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo O-I Glass Inc.

OI

O-I Glass Inc.

N/A

Current Price

$15.18

Market Cap

2.0B

ML Signal

N/A

Logo Supernus Pharmaceuticals Inc.

SUPN

Supernus Pharmaceuticals Inc.

N/A

Current Price

$48.70

Market Cap

2.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
OI
SUPN
Founded
1903
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Containers/Packaging
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
2.6B
IPO Year
N/A
2012

Fundamental Metrics

Financial Performance
Metric
OI
SUPN
Price
$15.18
$48.70
Analyst Decision
Buy
Strong Buy
Analyst Count
7
4
Target Price
$16.29
$63.25
AVG Volume (30 Days)
2.5M
658.9K
Earning Date
02-03-2026
11-04-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$6,455,000,000.00
$681,539,000.00
Revenue This Year
$1.41
$8.32
Revenue Next Year
$1.99
$23.36
P/E Ratio
N/A
N/A
Revenue Growth
N/A
4.54
52 Week Low
$9.23
$29.16
52 Week High
$16.04
$57.65

Technical Indicators

Market Signals
Indicator
OI
SUPN
Relative Strength Index (RSI) 66.54 59.46
Support Level $15.00 $45.36
Resistance Level $15.72 $47.26
Average True Range (ATR) 0.46 1.23
MACD 0.12 0.51
Stochastic Oscillator 78.78 88.31

Price Performance

Historical Comparison
OI
SUPN

About OI O-I Glass Inc.

O-I Glass is the world's largest manufacturer of glass bottles; 70% of its revenue comes from outside the United States. O-I has a leading position in key markets such as Europe, North America, and Brazil. Beer is the primary end market for O-I's glass bottles, which are also used for wine, soda, spirits, condiments, and food. O-I is looking to maintain or expand its dominant positions in Europe, North America, and South America.

About SUPN Supernus Pharmaceuticals Inc.

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.

Share on Social Networks: